EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adjuvant Pam3CSk4 does not improve the immunization against Cryptococcus gattii infection in C57BL/6 mice

Gabriela Yamazaki de Campos, Patrícia Kellen Martins Oliveira-Brito, Júlia Garcia Guimarães, Letícia Serafim da Costa, Javier Emílio Lazo Chica, Thiago Aparecido da Silva

PeerJ · 2023

DOI: 10.7717/peerj.14778 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2023. Verfasst von Gabriela Yamazaki de Campos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Molecular Biology and Pathogenic Bioagents, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil. Hauptthemen laut MEDLINE: Cryptococcosis, Cryptococcus gattii. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo a Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cryptococcosis is a relevant invasive fungal infection that affects immunocompromised and immunocompetent individuals when caused by Cryptococcus gattii . Host innate and adaptive immune responses can be subverted by C. gattii, that blocks the differentiation of T helper (Th) 1 and Th17 cells, which are involved in the protection against cryptococcosis. Moreover, the macrophage polarization is modulated by C. gattii infection that requires a balance in the macrophage subsets to control the C. gattii infection. Toll-like receptor (TLR) 2 agonists are important immunomodulators favoring a pro-inflammatory response with potential fungicidal activity, and TLR2 agonists have been used as adjuvants in vaccines against infections caused by bacteria or viruses. Therefore, this work aimed to evaluate the immunomodulatory effect of the tripalmitoyl lipopeptide S-glycerol cysteine (Pam3CSK4 or P3C4), a TLR2 agonist, as an adjuvant in the vaccination against C. gattii infection. Methods and Results C57BL/6 mice were immunized with 2 × 10 7 inactivated yeasts of C. gattii via intranasal route on day 1, 14 and 28 (Immunized group). Immunization was associated with 1µg or 10µg of adjuvant P3C4 (Immunized+P3C4-1µg or Immunized+P3C4-10 µg), followed by C. gattii infection on day 42 after the immunization protocol. Immunized+P3C4-1 µg group had reduced levels of IgG1, IgG2a and IgA and no significant difference in the IgG and IgM anti-GXM antibody titer was detected, compared to the Immunized group. High levels of IL-17 and IL-1 β in lung tissue of mice from the Immunized+P3C4-1µg group did not promote a predominance of Th17 cells, in contrast, the frequency of TLR2 + cells was increased in immunized mice that received 1 µg of P3C4. The reduction in the relative expression of T-bet and high levels of Foxp3 detected in the lungs of the Immunized+P3C4-1µg group suggest a prevalence of regulatory T cells in the tissue, which did not contribute to the control of C. gattii infection. The immunization protocol associated with 10 µg of adjuvant P3C4 induced high levels of IL-17 in the lung tissue, whereas the levels of pro-inflammatory cytokines were downregulated. To evaluate the effect of adjuvant P3C4 in the control of C. gattii infection, quantification of the fungal burden in the lungs was performed by the CFU assay, and the groups with adjuvant P3C4 showed a pulmonary C. gattii burden that was not significantly altered when compared with the immunized group. The mice that received 1 µg of adjuvant P3C4 had a lower percentage of inflammatory infiltrate in the lungs.

Conclusion

The immunomodulatory effect of P3C4, associated with the immunization protocol, plays an imbalance between pro- and anti-inflammatory response in the lungs that did not favor a protection against C. gattii infection, which is related to the immune response characterized by a suppressive/regulatory profile in the pulmonary microenvironment after C. gattii infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CryptococcosisCryptococcus gattiiAnimalsMiceInterleukin-17Toll-Like Receptor 2Mice, Inbred C57BLImmunizationVaccinationAdjuvants, Immunologic

Stichwörter der Autor:innen

Cryptococcus gattiiImmunomodulationPam3CSK4TLR2Vaccine

Substanzen

Interleukin-17Toll-Like Receptor 2Adjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Cell and Molecular Biology and Pathogenic Bioagents, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
  • Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
  • Institute of Natural and Biological Sciences, Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil.

Förderung

  • Fundação de Amparo a Pesquisa do Estado de São Paulo
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Zitieren

APA

de Campos, G. Y., Oliveira-Brito, P. K. M., Guimarães, J. G., da Costa, L. S., Lazo Chica, J. E., & da Silva, T. A. (2023). Adjuvant Pam3CSk4 does not improve the immunization against Cryptococcus gattii infection in C57BL/6 mice. PeerJ. https://doi.org/10.7717/peerj.14778

Vancouver

de Campos GY, Oliveira-Brito PKM, Guimarães JG, da Costa LS, Lazo Chica JE, da Silva TA. Adjuvant Pam3CSk4 does not improve the immunization against Cryptococcus gattii infection in C57BL/6 mice. PeerJ. 2023. doi:10.7717/peerj.14778

BibTeX
@article{deCampos2023,
  author = {de Campos, Gabriela Yamazaki and Oliveira-Brito, Patrícia Kellen Martins and Guimarães, Júlia Garcia and da Costa, Letícia Serafim and Lazo Chica, Javier Emílio and da Silva, Thiago Aparecido},
  title = {Adjuvant Pam3CSk4 does not improve the immunization against Cryptococcus gattii infection in C57BL/6 mice},
  journal = {PeerJ},
  year = {2023},
  doi = {10.7717/peerj.14778}
}
Kostenlos starten →